We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

114 hedge funds and large institutions have $209M invested in Cymabay Therapeutics in 2020 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 31 increasing their positions, 34 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

135% more capital invested

Capital invested by funds: $88.7M → $209M (+$120M)

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

50% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 24

23% more call options, than puts

Call options by funds: $2.07M | Put options by funds: $1.69M

12% more funds holding

Funds holding: 102 → 114 (+12)

9% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 34

Holders
114
Holders Change
+12
Holders Change %
+11.76%
% of All Funds
2.34%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.08%
New
36
Increased
31
Reduced
34
Closed
24
Calls
$2.07M
Puts
$1.69M
Net Calls
+$384K
Net Calls Change
-$571K

Top Buyers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
+$8.21M
2
SCM
Sio Capital Management
New York
+$6.25M
3
FCMI
Foresite Capital Management III
California
+$4.62M
4
BBA
Baker Bros. Advisors
New York
+$4.39M
5
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$2.99M

Top Sellers

Rank Fund Capital Flow
1
ECM
Engine Capital Management
New York
-$12.9M
2
Deutsche Bank
Deutsche Bank
Germany
-$8.01M
3
RG
Redmile Group
California
-$3.11M
4
IC
Ikarian Capital
Texas
-$2.42M
5
JP Morgan Chase
JP Morgan Chase
New York
-$2.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
PPA
26
Parametric Portfolio Associates
Washington
$2.01M +$1.17M +404,078 +234%
Point72 Asset Management
27
Point72 Asset Management
Connecticut
$2.01M +$1.66M +576,638 New
VVM
28
Versant Venture Management
California
$1.9M – – –
BCM
29
Bridgeway Capital Management
Texas
$1.74M +$988K +342,524 +221%
CS
30
Credit Suisse
Switzerland
$1.71M -$352K -122,067 -20%
Charles Schwab
31
Charles Schwab
California
$1.52M +$175K +60,665 +16%
Deutsche Bank
32
Deutsche Bank
Germany
$1.32M -$8.01M -2,775,270 -88%
UBS Group
33
UBS Group
Switzerland
$1.32M +$20.1K +6,965 +2%
Two Sigma Advisers
34
Two Sigma Advisers
New York
$1.3M +$58.9K +20,400 +6%
Hudson Bay Capital Management
35
Hudson Bay Capital Management
Connecticut
$1.17M +$346K +120,000 +56%
Bank of America
36
Bank of America
North Carolina
$1.16M -$122K -42,170 -11%
Two Sigma Investments
37
Two Sigma Investments
New York
$1.08M -$39.8K -13,794 -4%
Jacobs Levy Equity Management
38
Jacobs Levy Equity Management
New Jersey
$1.05M +$746K +258,617 +607%
CCM
39
Copernicus Capital Management
California
$1M +$828K +287,000 New
Morgan Stanley
40
Morgan Stanley
New York
$981K +$359K +124,573 +80%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$963K +$540K +187,162 +211%
Squarepoint
42
Squarepoint
New York
$953K +$270K +93,599 +52%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$936K -$43.2K -14,982 -5%
FI
44
Fosun International
China
$920K -$1.06M -368,858 -58%
N
45
Nuveen
North Carolina
$913K -$381K -131,867 -34%
Connor, Clark & Lunn Investment Management (CC&L)
46
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$856K +$372K +128,755 +110%
HIM
47
Hillsdale Investment Management
Ontario, Canada
$755K +$624K +216,300 New
DCM
48
DAFNA Capital Management
California
$578K +$478K +165,600 New
BFM
49
Boothbay Fund Management
New York
$557K -$159K -54,971 -26%
California Public Employees Retirement System
50
California Public Employees Retirement System
California
$535K +$164K +56,965 +59%
1
2
3 4 5

CBAY Hedge Fund Activity: Q2 2020 in Review

114 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2020, worth a combined $209M — up 135% from $88.7M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new CBAY positions and 24 closed out — a net gain of 12 holders — while 31 added to existing stakes and 34 trimmed.

The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $8.21M. The largest seller was Engine Capital Management, cutting an estimated $12.9M.

  • 114 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2020, up from 102 in Q1 2020.
  • Funds reported $209M of Cymabay Therapeutics stock for Q2 2020, up 135% quarter-over-quarter.
  • 36 funds opened new Cymabay Therapeutics positions in Q2 2020 and 24 closed out, a net change of +12 holders.
  • The largest Cymabay Therapeutics buyer in Q2 2020 was Foresite Capital Management IV, an estimated $8.21M added.
  • The largest Cymabay Therapeutics seller in Q2 2020 was Engine Capital Management, an estimated $12.9M sold.

Based on aggregated 13F filings for Q2 2020.